Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
01 2020
Historique:
received: 28 08 2019
revised: 03 11 2019
accepted: 05 11 2019
pubmed: 10 12 2019
medline: 31 7 2020
entrez: 9 12 2019
Statut: ppublish

Résumé

Neurocognitive changes are well described after prophylactic or therapeutic whole-brain radiotherapy (WBRT) and have been reported as early as 3 months after radiotherapy (RT). Therefore, WBRT with protection of the hippocampal region (hippocampal avoidance, HA) has been proposed to preserve neurocognition. Our aim was to compare the risk of leukoencephalopathy after prophylactic cranial irradiation (PCI) with or without HA. Patients with small-cell lung cancer who received either lateral-opposed field PCI (non-HA-PCI; n = 9) or hippocampus avoidance PCI (HA-PCI; n = 9) with available magnetic resonance imaging (MRI) follow-up were identified and age matched. Pre-therapeutic and follow-up MRI after RT was analysed for leukoencephalopathy based on the Fazekas score. Bilateral cortical and subcortical brain structures were segmented and analysed for alterations in dosimetric parameters and volumes. There was no significant difference of Fazekas scores between groups at baseline. Fazekas score differed in post-treatment with a median of 1 in the HA-PCI group and 2 in the non-HA-PCI group (p = 0.007). Significant increase of Fazekas score over time after RT was observed for HA-PCI patients (p = 0.001) but not for non-HA-PCI patients. Dmax (highest radiation dose) and brain volume receiving doses >25Gy were higher in HA-PCI patients. There were no significant volumetric differences for segmented brain structures between groups. Radiological changes are more prominent after HA-PCI than after non-HA-PCI. Although no standardised neurocognitive testing was performed, the significantly increased Fazekas scores after HA-PCI are expected to interfere with neurocognitive function. Prospective long-term neurocognitive studies are warranted before HA-PCI is implemented in routine clinical practice.

Identifiants

pubmed: 31812935
pii: S0959-8049(19)30817-2
doi: 10.1016/j.ejca.2019.11.008
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

194-203

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Michael Mayinger (M)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland. Electronic address: michaelchristian.mayinger@usz.ch.

Johannes Kraft (J)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Niklas Lohaus (N)

Department of Neuroradiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Michael Weller (M)

Department of Neurology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Daniel Schanne (D)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Jana Heitmann (J)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Jonas Willmann (J)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Lotte Wilke (L)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Jérôme Krayenbuehl (J)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Stephanie Tanadini-Lang (S)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Matthias Guckenberger (M)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Nicolaus Andratschke (N)

Department of Radiation Oncology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH